Latest News
Alcester, Warwickshire, UK. 24 November 2020. Seroba’s portfolio company, Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a medical technology company developing innovative dialysis products and services, has announced the appointment of John S. Lipman as […]
Storm’s First-in-Class clinical candidate against an RNA Methyltransferase for use in Cancer was identifed with support from Evotec’s Drug Discovery Engine. Storm will progress the compound towards the clinic using indigo, Evotec’s integrated Ivestigational New Drug […]
MILPITAS, Calif. November 12, 2020. Seroba’s portfolio company, PQ Bypass, Inc, a medical device pioneer bringing new advancements to the treatment of complex peripheral artery disease (PAD), announced promising long-term safety and effectiveness results from 24-month […]
USA and Ireland. 10 November, 2020. Seroba’s portfolio company, Atlantic Therapeutics, has announced that Heidi Zak, co-founder and CEO of ThirdLove will take on an advisory role in the acceleration of the INNOVO® brand. INNOVO® is […]
Hamilton, Ontario and Boston, 2 November 2020. Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced a collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) to develop and commercialize […]
Cambridge, UK. 22 October 2020. Seroba’s investee company, STORM Therapeutics, the leading biotechnology company focused on the discovery and development of small molecule therapies modulating RNA epigenetics, has announced that STC-15, its first-in-class drug candidate targeting […]
Dublin, Ireland. 9 September 2020. FutureNeuro has announced that it has entered into partnership with Seroba’s portfolio company, STORM Therapeutics, the leading biotechnology company focused on the discovery and development of small molecule therapies modulating RNA […]
MILPITAS, California. September 2, 2020. PQ Bypass Inc, a medical device pioneer bringing new advancements to the treatment of advanced peripheral artery disease (PAD), announced today that they received Breakthrough Device designation from the U.S. Food and […]
Galway, Ireland. 14 July 2020. Seroba’s portfolio company, Atlantic Therapeutics, a Galway-based MedTech and Femtech innovator, announces a transition in leadership to fulfill the potential of the INNOVO® brand in the large and under-served US Stress […]
Hamilton, Ontario and Boston. 25 June 2020. Fusion Pharmaceuticals Inc. (NASDAQ: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the pricing of its initial public offering of 12,500,000 common […]